Evolent Health (EVH) Q2 FY26 earnings call

Evolent Health delivered strong Q2 FY26 results, driven by significant Performance Suite growth and successful launches with Highmark and Aetna. The company raised its full-year revenue and adjusted EBITDA guidance, while also announcing a major new oncology partnership and demonstrating meaningful scale with its AI-powered Auth Intelligence platform. Despite anticipated headwinds from Medicaid and exchange membership attrition in 2027, management expressed confidence in delivering strong adjusted EBITDA growth through operational efficiencies and continued Performance Suite expansion.